These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27191492)

  • 1. Drug development: A healthy pipeline.
    Morgan B
    Nature; 2016 May; 533(7603):S116-7. PubMed ID: 27191492
    [No Abstract]   [Full Text] [Related]  

  • 2. Board Review Vignette: Irritable Bowel Syndrome.
    Talley NJ
    Am J Gastroenterol; 2016 Sep; 111(9):1223-5. PubMed ID: 27527743
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapy for irritable bowel syndrome.
    Lacy BE
    N Engl J Med; 2004 Mar; 350(12):1261-3; author reply 1261-3. PubMed ID: 15031865
    [No Abstract]   [Full Text] [Related]  

  • 4. Modern Management of Irritable Bowel Syndrome: More Than Motility.
    Tack J; Vanuytsel T; Corsetti M
    Dig Dis; 2016; 34(5):566-73. PubMed ID: 27331917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irritable bowel syndrome.
    Mertz HR
    N Engl J Med; 2003 Nov; 349(22):2136-46. PubMed ID: 14645642
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacological treatment of irritable bowel syndrome--from concept to sales.
    Kamm MA
    Eur J Surg Suppl; 2002; (587):10-5. PubMed ID: 16144196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary and pharmacological treatment of abdominal pain in IBS.
    Camilleri M; Boeckxstaens G
    Gut; 2017 May; 66(5):966-974. PubMed ID: 28232472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
    Nee J; Zakari M; Lembo AJ
    Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy for irritable bowel syndrome.
    Olden KW
    N Engl J Med; 2004 Mar; 350(12):1261-3; author reply 1261-3. PubMed ID: 15028836
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of serotonin in irritable bowel syndrome: implications for management.
    Garvin B; Wiley JW
    Curr Gastroenterol Rep; 2008 Aug; 10(4):363-8. PubMed ID: 18627647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiological, pathophysiological and therapeutic impact of the enteric serotonergic system.
    Molderings GJ
    Arzneimittelforschung; 2012 Apr; 62(4):157-66. PubMed ID: 22438071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual role of serotonin in the pathogenesis of indomethacin-induced small intestinal ulceration: pro-ulcerogenic action via 5-HT3 receptors and anti-ulcerogenic action via 5-HT4 receptors.
    Kato S; Matsuda N; Matsumoto K; Wada M; Onimaru N; Yasuda M; Amagase K; Horie S; Takeuchi K
    Pharmacol Res; 2012 Sep; 66(3):226-34. PubMed ID: 22699012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A; Boznańska P
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irritable bowel syndrome genophenomics: correlation of serotonin-transporter polymorphisms and alosetron response.
    Scherl E; Frissora CL
    Pharmacogenomics J; 2003; 3(2):64-6. PubMed ID: 12746730
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drug treatment of irritable bowel syndrome: an unmet need].
    Mearin F
    Gastroenterol Hepatol; 2007 Mar; 30(3):130-7. PubMed ID: 17374325
    [No Abstract]   [Full Text] [Related]  

  • 17. The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
    Salaga M; Binienda A; Tichkule RB; Thakur GA; Makriyannis A; Storr M; Fichna J
    Eur J Pharmacol; 2018 Oct; 836():34-43. PubMed ID: 30121173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripherally acting therapies for the treatment of irritable bowel syndrome.
    Saad RJ
    Gastroenterol Clin North Am; 2011 Mar; 40(1):163-82. PubMed ID: 21333906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of piperazinylpyridine derivatives as novel 5-HT1A agonists/5-HT3 antagonists for the treatment of irritable bowel syndrome (IBS).
    Asagarasu A; Matsui T; Hayashi H; Tamaoki S; Yamauchi Y; Sato M
    Chem Pharm Bull (Tokyo); 2009 Jan; 57(1):34-42. PubMed ID: 19122313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
    Manning DD; Cioffi CL; Usyatinsky A; Fitzpatrick K; Masih L; Guo C; Zhang Z; Choo SH; Sikkander MI; Ryan KN; Naginskaya J; Hassler C; Dobritsa S; Wierschke JD; Earley WG; Butler AS; Brady CA; Barnes NM; Cohen ML; Guzzo PR
    Bioorg Med Chem Lett; 2011 Jan; 21(1):58-61. PubMed ID: 21146988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.